Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. [electronic resource]
Producer: 20111007Description: 657-64 p. digitalISSN:- 1524-4733
- Adenine -- analogs & derivatives
- Adult
- Alkynes
- Anti-HIV Agents -- economics
- Antiretroviral Therapy, Highly Active
- Benzoxazines -- economics
- CD4 Lymphocyte Count
- Clinical Trials as Topic
- Cost Savings
- Cost-Benefit Analysis
- Cyclopropanes
- Deoxycytidine -- analogs & derivatives
- Dideoxynucleosides -- economics
- Drug Costs
- Emtricitabine
- Female
- HIV Infections -- diagnosis
- Health Services Research
- Humans
- Lamivudine -- economics
- Male
- Markov Chains
- Models, Economic
- Organophosphonates -- economics
- Outcome and Process Assessment, Health Care -- economics
- Quality-Adjusted Life Years
- Reverse Transcriptase Inhibitors -- economics
- Tenofovir
- Time Factors
- Treatment Outcome
- United States -- epidemiology
- Viral Load
- Zidovudine -- economics
No physical items for this record
Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.